Logo

Innovent Receives the NMPA's Approval for Byvasda (biosimilar- bevacizumab) to Treat Non-Small Cell Lung Cancer and Metastatic Colorectal Cancer in China

Share this

Innovent Receives the NMPA's Approval for Byvasda (biosimilar- bevacizumab) to Treat Non-Small Cell Lung Cancer and Metastatic Colorectal Cancer in China

Shots:

  • The NMPA has approved Byvasda for the treatment of patients with NSCLC and metastatic colorectal cancer. The approval follows TYVYT (sintilimab injection) approval- indicated to treat patients with Hodgkin's lymphoma- granted in Dec’2018
  • The launch of Byvasda will provide Chinese patients with high-quality and relatively more affordable bevacizumab biosimilar injection
  • In Jan’2020- Innovent granted commercial rights of Byvasda to in the US and Canada to Coherus BioSciences. Byvasda is a recombinant humanized anti-VEGF mAb targeting VEGF receptors on the surface of vascular endothelial cells- thus inhibiting signaling pathways such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK

Click here to read full press release/ article 

Ref: Buinesswire | Image: Innovent


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions